GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » PS Ratio

BridgeBio Pharma (BridgeBio Pharma) PS Ratio : 426.84 (As of Apr. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BridgeBio Pharma's share price is $24.33. BridgeBio Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.06. Hence, BridgeBio Pharma's PS Ratio for today is 426.84.

The historical rank and industry rank for BridgeBio Pharma's PS Ratio or its related term are showing as below:

BBIO' s PS Ratio Range Over the Past 10 Years
Min: 12.57   Med: 101.45   Max: 1015.86
Current: 441.83

During the past 7 years, BridgeBio Pharma's highest PS Ratio was 1015.86. The lowest was 12.57. And the median was 101.45.

BBIO's PS Ratio is ranked worse than
93.64% of 991 companies
in the Biotechnology industry
Industry Median: 8.98 vs BBIO: 441.83

BridgeBio Pharma's Revenue per Sharefor the three months ended in Dec. 2023 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.06.

Warning Sign:

BridgeBio Pharma Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of BridgeBio Pharma was -89.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -6.60% per year.

During the past 7 years, BridgeBio Pharma's highest 3-Year average Revenue per Share Growth Rate was 10.90% per year. The lowest was -6.60% per year. And the median was 2.15% per year.

Back to Basics: PS Ratio


BridgeBio Pharma PS Ratio Historical Data

The historical data trend for BridgeBio Pharma's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma PS Ratio Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial 90.80 1,015.86 34.53 14.46 708.25

BridgeBio Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.46 31.28 464.86 439.50 708.25

Competitive Comparison of BridgeBio Pharma's PS Ratio

For the Biotechnology subindustry, BridgeBio Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BridgeBio Pharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's PS Ratio falls into.



BridgeBio Pharma PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

BridgeBio Pharma's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=24.33/0.057
=426.84

BridgeBio Pharma's Share Price of today is $24.33.
BridgeBio Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


BridgeBio Pharma  (NAS:BBIO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


BridgeBio Pharma PS Ratio Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BridgeBio Pharma (BridgeBio Pharma) Business Description

Traded in Other Exchanges
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Executives
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Frank Mccormick officer: Chairman of Oncology C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Neil Kumar director, officer: See Remarks C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Brian C Stephenson officer: See Remarks 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille director 175 WATER STREET, NEW YORK NY 10038
Andrew Lo director C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Ronald J Daniels director C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee director 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders director 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Andrea Ellis director C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Richard H Scheller director, officer: See Remarks C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990

BridgeBio Pharma (BridgeBio Pharma) Headlines